BOSTON — Sparsentan, a first-in-class, oral dual endothelin-angiotensin receptor antagonist, shows significant benefit in reducing proteinuria in the difficult-to-manage focal segmental ...

UK Guidelines > Read summaries of UK clinical guidelines on diseases and specialties such as diabetes, oncology, mental health, respiratory disorders, women's health, cardiology, and more.

BOSTON — Adults recently diagnosed with immunoglobulin A nephropathy who were assigned sparsentan as first-line therapy experienced rapid and sustained reductions in proteinuria, according to ...

(Getty Images) Sparsentan consistently lowered urine protein/creatinine ratios in a small heterogenous group of individuals with IgAN. The case series demonstrates the efficacy of sparsentan in ...

BOSTON—Proteinuria dropped nearly 70% over 24 weeks in patients with newly diagnosed immunoglobulin A nephropathy (IgAN) treated with sparsentan, according to an abstract that will be presented at the ...

Travere Therapeutics is likely to be the first beneficiary of these recommendations, having filed a supplemental New Drug Application (sNDA) for Filspari (sparsentan) for FSGS treatment on March 17, ...

Travere Therapeutics is likely to be the first beneficiary of these recommendations, having filed a supplemental New Drug Application (sNDA) for Filspari (sparsentan) for FSGS treatment on March ...

Die von Franz Fischer und seinem Mitarbeiter Hans Tropsch am damaligen Kaiser-Wilhelm-Institut für Kohlenforschung entdeckte Fischer-Tropsch-Synthese ist wohl eine der vielseitigsten chemischen ...

The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary immunoglobulin A (IgA) nephropathy, maker Novartis announced late on Wednesday.

"Deshalb haben wir aus Sicherheitsgründen zunächst nur zwei Milligramm hergestellt." Synthese bietet große Vorteile für die Forschung Der Naturstoff wird normalerweise von Bakterien produziert.